Skytech Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
- Paid Up Capital ₹ 0.17 M
- Company Age 20 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 5.00 M
- Revenue Growth -13.39%
- Profit Growth -5.08%
- Ebitda 6.49%
- Net Worth 6.36%
- Total Assets -9.87%
About Skytech Pharma
Skytech Pharma Private Limited (SPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 01 July 2004 and has a history of 20 years and seven months. Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.17 M.
The company has closed loans amounting to ₹5.00 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Pinky Jindal, Jatin Jindal, and Mannu Gupta serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24233DL2004PTC127312
- Company No.
127312
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Jul 2004
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Skytech Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pinky Jindal  | Director | 31-Mar-2008 | Current |
| Jatin Jindal | Director | 01-Apr-2015 | Current |
| Mannu Gupta | Director | 16-Dec-2015 | Current |
Financial Performance of Skytech Pharma.
Skytech Pharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 13.39% decrease. The company also saw a slight decrease in profitability, with a 5.08% decrease in profit. The company's net worth moved up by a moderate rise of 6.36%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Skytech Pharma?
In 2023, Skytech Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0
₹5.00 M
Charges Breakdown by Lending Institutions
- Central Bank Of India : 0.50 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 23 Jul 2011 | Central Bank Of India | ₹5.00 M | Satisfied |
How Many Employees Work at Skytech Pharma?
Unlock and access historical data on people associated with Skytech Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Skytech Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Skytech Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
